Orion Portfolio Solutions LLC Purchases 2,065 Shares of Boston Scientific Co. (NYSE:BSX)

Orion Portfolio Solutions LLC grew its position in Boston Scientific Co. (NYSE:BSX) by 7.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,580 shares of the medical equipment provider’s stock after purchasing an additional 2,065 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Boston Scientific were worth $2,731,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. D.A. Davidson & CO. grew its holdings in Boston Scientific by 3.2% during the 3rd quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider’s stock worth $917,000 after acquiring an additional 342 shares during the period. Glenmede Trust Co. NA grew its stake in Boston Scientific by 19.0% during the third quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider’s stock worth $1,715,000 after purchasing an additional 3,261 shares during the period. CreativeOne Wealth LLC increased its holdings in Boston Scientific by 62.0% in the third quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider’s stock worth $375,000 after purchasing an additional 1,714 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Boston Scientific by 10.6% in the third quarter. Rockefeller Capital Management L.P. now owns 137,964 shares of the medical equipment provider’s stock valued at $11,536,000 after buying an additional 13,268 shares during the period. Finally, Icon Wealth Advisors LLC bought a new position in shares of Boston Scientific during the 3rd quarter worth approximately $100,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

BSX opened at $100.95 on Tuesday. Boston Scientific Co. has a 12-month low of $66.80 and a 12-month high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a 50-day moving average price of $102.20 and a 200-day moving average price of $93.30. The stock has a market capitalization of $149.30 billion, a P/E ratio of 80.76, a PEG ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BSX shares. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Friday, January 10th. Morgan Stanley boosted their target price on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Stifel Nicolaus increased their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company boosted their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock worth $14,319,269 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.